Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: Fierce 15 nominations are now open! We're looking for the best and brightest in biotech.
Connect Biopharmaceuticals
Biotech
Connect uncouples from Pfizer by scrapping eczema pact
Connect licensed the oral, peripherally acting H3R antagonist in 2012 from Arena, a company that Pfizer bought for $6.7 billion a decade later.
Nick Paul Taylor
Apr 17, 2024 6:38am
Connect blames 'challenging environment' for lead program pause
Jan 3, 2023 7:55am
Chasing BMS and Pfizer, Connect fails ulcerative colitis trial
May 4, 2022 7:53am
Connect Biopharma touts positive data for Dupixent rival
Nov 22, 2021 5:30am
Connect Biopharma nabs $115M as it eyes rivalry with Dupixent
Aug 25, 2020 7:25am